Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R0BX
|
|||
| Former ID |
DAP000998
|
|||
| Drug Name |
Nitrofurantoin
|
|||
| Synonyms |
Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Furabid; Furachel; Furadantin; Furadantine; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Gerofuran; Ituran; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; NITROFURANTION; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitrofuradantin; Nitrofurantoina; Nitrofurantoine; Nitrofurantoinum; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Siraliden; Trantoin; Uerineks; Urantoin; Urizept; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Welfurin; Zoofurin; Fua Med; Furadantin Retard; Furadantina MC; Furadantine mc; Furophen T; NITROFURANTOIN MACROCRYSTALLINE; Nitrofurantoina [DCIT]; Fua-med; Fur-ren; Furadantin (TN); Furadantine-MC; Macrobid (TN); Macrodantin (TN); N-Toin; ND-3320; ND-7248; NITROFURANTOIN, MACROCRYSTALLINE; Nitro Macro (TN); Nitrofur-C; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Ro-Antoin; Urantoin (TN); Uro-Selz; Uro-Tablinen; Uro-tablineu; Usaf ea-2; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Urinary tract infection [ICD-11: GC08; ICD-10: N39, N39.0; ICD-9: 599] | Approved | [1] | |
| Therapeutic Class |
Antiinfective Agents
|
|||
| Company |
Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H6N4O5
|
|||
| Canonical SMILES |
C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-]
|
|||
| InChI |
1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
|
|||
| InChIKey |
NXFQHRVNIOXGAQ-YCRREMRBSA-N
|
|||
| CAS Number |
CAS 67-20-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9477, 603042, 3347076, 7847505, 7980134, 8139874, 8149444, 10321408, 10532352, 14749496, 17389788, 24640067, 26611838, 26679707, 26747377, 43223979, 47425320, 47574396, 47796070, 47944823, 48170470, 48319506, 48394923, 48414143, 48416333, 48423850, 48425399, 49699064, 49855694, 50105610, 50105611, 50344367, 53788524, 57288795, 57371029, 72200890, 81041227, 81093030, 85787883, 88313616, 92124245, 92125001, 92307346, 93166339, 99301312, 103179088, 103913903, 104170019, 106225506, 114637257
|
|||
| ChEBI ID |
CHEBI:71415
|
|||
| ADReCS Drug ID | BADD_D01576 ; BADD_D01577 ; BADD_D01578 | |||
| SuperDrug ATC ID |
J01XE01
|
|||
| SuperDrug CAS ID |
cas=000067209
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [2] | |||
| Experimental Method | High-throughput screening | |||
| Description | Nitrofurantoin can be metabolized by gut microbiota. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Alistipes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Alistipes was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Bacteroides was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Nitrofurantoin (adjusted p-values: 5.58E-05). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Nitrofurantoin (adjusted p-values: 8.58E-04). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Nitrofurantoin (adjusted p-values: 4.30E-03). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides thetaiotaomicron was decreased by Nitrofurantoin (adjusted p-values: 2.70E-05). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Nitrofurantoin (adjusted p-values: 6.81E-04). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Nitrofurantoin (adjusted p-values: 2.89E-04). | |||
|
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides xylanisolvens was decreased by Nitrofurantoin (adjusted p-values: 6.78E-04). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Nitrofurantoin (adjusted p-values: 2.14E-04). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Nitrofurantoin (adjusted p-values: 1.12E-04). | |||
|
Studied Microbe: Prevotella
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Prevotella was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Nitrofurantoin (adjusted p-values: 3.33E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was increased by Nitrofurantoin. | |||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Bifidobacterium was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium adolescentis was decreased by Nitrofurantoin (adjusted p-values: 3.19E-05). | |||
|
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium longum was decreased by Nitrofurantoin (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Nitrofurantoin (adjusted p-values: 2.74E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eggerthella lenta was decreased by Nitrofurantoin (adjusted p-values: 1.11E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Enterobacteriaceae was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli ED1a was decreased by Nitrofurantoin (adjusted p-values: 8.02E-05). | |||
|
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli IAI1 was decreased by Nitrofurantoin (adjusted p-values: 3.78E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Erysipelatoclostridium ramosum was decreased by Nitrofurantoin (adjusted p-values: 1.66E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Blautia was increased by Nitrofurantoin. | |||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Nitrofurantoin (adjusted p-values: 1.52E-06). | |||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Nitrofurantoin (adjusted p-values: 2.87E-05). | |||
|
Studied Microbe: Coprococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Coprococcus was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Nitrofurantoin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Dorea
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Dorea was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Nitrofurantoin (adjusted p-values: 5.43E-06). | |||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Nitrofurantoin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Eubacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Eubacterium was decreased by Nitrofurantoin. | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Nitrofurantoin (adjusted p-values: 3.05E-03). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Nitrofurantoin (adjusted p-values: 1.69E-04). | |||
|
Studied Microbe: Roseburia
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Roseburia was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Nitrofurantoin (adjusted p-values: 1.70E-05). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Nitrofurantoin (adjusted p-values: 1.49E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Nitrofurantoin (adjusted p-values: 2.18E-04). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Nitrofurantoin (adjusted p-values: 1.36E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Enterococcus was not significantly changed by Nitrofurantoin. | |||
|
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus parasanguinis was decreased by Nitrofurantoin (adjusted p-values: 8.66E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Veillonella parvula was decreased by Nitrofurantoin (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Urinary tract infection | |||
| Description | The abundance of Akkermansia was not significantly changed by Nitrofurantoin. | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Deoxyribonucleic acid (Bact DNA) | Target Info | Breaker | [7] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009175. | |||
| REF 2 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 3 | Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clin Microbiol Infect. 2015 Apr;21(4):344.e1-11. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota. J Antimicrob Chemother. 2015 Jul;70(7):1989-92. | |||
| REF 6 | Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. J Chemother. 1997 Jun;9(3):203-7. | |||
| REF 7 | On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.